July 01, 2025 09:00 ET | Source: Inmagene Biopharmaceuticals The ADAPTIVE Phase 2b trial evaluates multiple dose regimens of IMG-007…
Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer (mPDAC) treated with elraglusib June 20,…
June 16, 2025 19:20 ET | Source: PolyPid Ltd. The Company Anticipates that with this Additional Funding, PolyPid’s Runway would…
TAINAN, June 13, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial…
June 06, 2025 16:05 ET | Source: PolyPid Ltd. PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD),…
June 06, 2025 16:07 ET | Source: Restem MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology…
LEHI, Utah, June 4, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies inspired by genetic resilience, today…